Drug Search Results
More Filters [+]

Sulbactam

Alternative Names: sulbactam, Sulbactam-Durlobactam, SUL-DUR, unasyn
Latest Update: 2024-09-04
Latest Update Note: News Article

Product Description

Sulbactam is in a class of medications called beta-lactamase inhibitors. It works by preventing bacteria from destroying ampicillin. (Sourced from: https://medlineplus.gov/druginfo/meds/a693021.html)

Mechanisms of Action: LACTB Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Austria | Brazil | Bulgaria | Chile | China | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | Estonia | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Korea | Lithuania | Malaysia | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Spain | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sulbactam

Countries in Clinic: Belarus, Brazil, China, Greece, Hungary, India, Israel, Korea, Lithuania, Mexico, Peru, Puerto Rico, Russia, Taiwan, Thailand, Turkey, United States, Unknown Location

Active Clinical Trial Count: 9

Highest Development Phases

Phase 3: Acinetobacter Infections|Bacteremia|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated|Respiratory Tract Infections|Urinary Tract Infections

Phase 2: Bronchiectasis|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Pneumonia|Pyelonephritis

Phase 1: Arthritis, Infectious|Bacteriuria|Cellulitis|Cystitis|Erysipelas|Gonorrhea|Healthy Volunteers|Lung Abscess|Meningitis, Bacterial|Osteoarthritis|Osteomyelitis|Pelvic Infection|Peritonitis|Pharyngitis|Sepsis|Sinusitis|Soft Tissue Infections|Tonsillitis|Wound Infection

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2020-001397-30

P3

Active, not recruiting

Unknown

2024-09-03

2018-002526-23

P3

Completed

Acinetobacter Infections

2021-07-26

ATTACK

P3

Completed

Bacteremia|Pneumonia, Ventilator-Associated|Pneumonia, Bacterial|Acinetobacter Infections

2021-07-26

CTR20130509

P1

Recruiting

Erysipelas|Pneumonia, Bacterial|Bronchiectasis|Peritonitis|Cellulitis|Bacteriuria|Pelvic Infection|Arthritis, Infectious|Bronchitis, Chronic|Sinusitis|Lung Abscess|Osteomyelitis|Osteoarthritis|Wound Infection|Pyelonephritis|Respiratory Tract Infections|Sepsis|Urinary Tract Infections|Gonorrhea|Meningitis, Bacterial|Soft Tissue Infections|Tonsillitis|Pharyngitis|Cystitis

None

Recent News Events